LONDON, Dec 6 (Reuters) – AstraZeneca’s pill
Tagrisso cut the risk of lung cancer progressing by 70 percent
compared to standard chemotherapy in a major clinical trial,
lifting prospects for a drug…
The post AstraZeneca pill slashes lung cancer progression in study appeared first on NASDAQ.